Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2013 Jan 17

PMID 23322901

Citations 105

Authors

Roisin M Connolly

Nguyen K Nguyen

Saraswati Sukumar

Affiliations

Soon will be listed here.

Abstract

Retinoids and their naturally metabolized and synthetic products (e.g., all-trans retinoic acid, 13-cis retinoic acid, bexarotene) induce differentiation in various cell types. Retinoids exert their actions mainly through binding to the nuclear retinoic acid receptors (α, β, γ), which are transcriptional and homeostatic regulators with functions that are often compromised early in neoplastic transformation. The retinoids have been investigated extensively for their use in cancer prevention and treatment. Success has been achieved with their use in the treatment of subtypes of leukemia harboring chromosomal translocations. Promising results have been observed in the breast cancer prevention setting, where fenretinide prevention trials have provided a strong rationale for further investigation in young women at high risk for breast cancer. Ongoing phase III randomized trials investigating retinoids in combination with chemotherapy in non-small cell lung cancer aim to definitively characterize the role of retinoids in this tumor type. The limited treatment success observed to date in the prevention and treatment of solid tumors may relate to the frequent epigenetic silencing of RARβ. Robust evaluation of RARβ and downstream genes may permit optimized use of retinoids in the solid tumor arena.

Citing Articles

Alcohol Consumption and Breast and Ovarian Cancer Development: Molecular Pathways and Mechanisms.

Fanfarillo F, Caronti B, Lucarelli M, Francati S, Tarani L, Ceccanti M Curr Issues Mol Biol. 2024; 46(12):14438-14452.

PMID: 39727994 PMC: 11674816. DOI: 10.3390/cimb46120866.

Antiproliferative and Morphological Effects of Fenretinide Lipid Nanosystems in Colon Adenocarcinoma Cells.

Anconelli L, Farioli F, Lodeserto P, Andreadi A, Borsetti F, Voltattorni M Pharmaceutics. 2024; 16(11).

PMID: 39598544 PMC: 11597870. DOI: 10.3390/pharmaceutics16111421.

All-Trans Retinoic Acid-Induced Cell Surface Heat Shock Protein 90 Mediates Tau Protein Internalization and Degradation in Human Microglia.

Nguyen N, Hoang T, Kim J Mol Neurobiol. 2024; 62(1):742-755.

PMID: 38900367 PMC: 11711573. DOI: 10.1007/s12035-024-04295-1.

Pin1-catalyzed conformational regulation after phosphorylation: A distinct checkpoint in cell signaling and drug discovery.

Lu K, Zhou X Sci Signal. 2024; 17(841):eadi8743.

PMID: 38889227 PMC: 11409840. DOI: 10.1126/scisignal.adi8743.

Vitamins in Gynecologic Malignancies.

Wierzbowska N, Olszowski T, Chlubek D, Kozlowski M, Cymbaluk-Ploska A Nutrients. 2024; 16(9).

PMID: 38732639 PMC: 11085130. DOI: 10.3390/nu16091392.

References

Hua S, Kittler R, White K . Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 2009; 137(7):1259-71. PMC: 3374131. DOI: 10.1016/j.cell.2009.04.043. View

Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov S, Gottfried M . Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol. 2008; 26(11):1886-92. DOI: 10.1200/JCO.2007.12.2614. View

Chiesa M, Passalacqua R, Michiara M, Franciosi V, Di Costanzo F, Bisagni G . Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial. Acta Biomed. 2008; 78(3):204-9. View

Cassidy J, Lippman M, Lacroix A, Peck G . Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. Eur J Cancer Clin Oncol. 1982; 18(10):925-8. DOI: 10.1016/0277-5379(82)90239-5. View

Moghal N, Neel B . Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer. Mol Cell Biol. 1995; 15(7):3945-59. PMC: 230634. DOI: 10.1128/MCB.15.7.3945. View

Pandolfi P . Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet. 2001; 10(7):769-75. DOI: 10.1093/hmg/10.7.769. View

Ren M, Pozzi S, Bistulfi G, Somenzi G, Rossetti S, Sacchi N . Impaired retinoic acid (RA) signal leads to RARbeta2 epigenetic silencing and RA resistance. Mol Cell Biol. 2005; 25(23):10591-603. PMC: 1291229. DOI: 10.1128/MCB.25.23.10591-10603.2005. View

Bushue N, Wan Y . Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 2010; 62(13):1285-98. PMC: 2991380. DOI: 10.1016/j.addr.2010.07.003. View

Wang Q, Lee D, Sysounthone V, Chandraratna RAS , Christakos S, Korah R . 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat. 2001; 67(2):157-68. DOI: 10.1023/a:1010643323268. View

10.

White J, Guo Y, Dilworth F, Bonasoro J, Jones G, Petkovich M . cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J Biol Chem. 1997; 272(30):18538-41. DOI: 10.1074/jbc.272.30.18538. View

11.

Raffoux E, Cras A, Recher C, Boelle P, de Labarthe A, Turlure P . Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget. 2011; 1(1):34-42. PMC: 4053545. DOI: 10.18632/oncotarget.106. View

12.

Freemantle S, Spinella M, Dmitrovsky E . Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003; 22(47):7305-15. DOI: 10.1038/sj.onc.1206936. View

13.

Sirchia S, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R . Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002; 62(9):2455-61. View

14.

Lippman S, Lee J, Karp D, Vokes E, Benner S, Goodman G . Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001; 93(8):605-18. DOI: 10.1093/jnci/93.8.605. View

15.

Houle B, Rochette-Egly C, BRADLEY W . Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. Proc Natl Acad Sci U S A. 1993; 90(3):985-9. PMC: 45795. DOI: 10.1073/pnas.90.3.985. View

16.

Liu Y, Lee M, Wang H, Li Y, Hashimoto Y, Klaus M . Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol. 1996; 16(3):1138-49. PMC: 231096. DOI: 10.1128/MCB.16.3.1138. View

17.

Duong V, Rochette-Egly C . The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim Biophys Acta. 2010; 1812(8):1023-31. DOI: 10.1016/j.bbadis.2010.10.007. View

18.

Khuri F, Rigas J, Figlin R, Gralla R, Shin D, Munden R . Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2001; 19(10):2626-37. DOI: 10.1200/JCO.2001.19.10.2626. View

19.

Lu T, Li W, Chen R, Fan Q, Wang L, Wang R . Inhibition effects of all trans-retinoic acid on the growth and angiogenesis of esophageal squamous cell carcinoma in nude mice. Chin Med J (Engl). 2011; 124(17):2708-14. View

20.

Lin L, Li B, Xiao J, Lin D, Yang B . Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World J Gastroenterol. 2005; 11(36):5633-7. PMC: 4481479. DOI: 10.3748/wjg.v11.i36.5633. View